JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toyama, T.
Right arrow Articles by Taniguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyama, T.
Right arrow Articles by Taniguchi, K.
Journal of Nuclear Medicine Vol. 44 No. 10 1604-1611
© 2003 by Society of Nuclear Medicine


Clinical Investigations

Efficacy of Carvedilol Treatment on Cardiac Function and Cardiac Sympathetic Nerve Activity in Patients with Dilated Cardiomyopathy: Comparison with Metoprolol Therapy

Takuji Toyama, MD, Hiroshi Hoshizaki, MD, Ryotaro Seki, MD, Naoki Isobe, MD, Hitoshi Adachi, MD, Shigeto Naito, MD, Shigeru Oshima, MD and Koichi Taniguchi, MD

Gunma Prefectural Cardiovascular Center, Maebashi, Japan

Carvedilol and metoprolol have been reported to be effective in the treatment of patients with chronic heart failure. However, to our knowledge, there have been no studies comparing the effects of the 2 drugs on cardiac function, including cardiac sympathetic nerve activity. Methods: We compared 15 patients with dilated cardiomyopathy (DCM) who were receiving carvedilol (group A) with 15 patients with DCM who were receiving metoprolol (group B). Before and after 1 y of treatment, cardiac 123I-metaiodobenzylguanidine (123I-MIBG) uptake was assessed using the total defect score (TDS) and the heart-to-mediastinum (H/M) activity ratio from the delayed images. The New York Heart Association (NYHA) class and echocardiographic left ventricular ejection fraction (LVEF) also were assessed. Results: In both groups, the TDS decreased (in group A, from 25 ± 14 to 16 ± 14, P < 0.01; in group B, from 27 ± 9 to 19 ± 10, P < 0.01), the H/M increased (in group A, from 1.67 ± 0.31 to 2.01 ± 0.36, P < 0.01; in group B, from 1.68 ± 0.21 to 1.93 ± 0.32, P < 0.01), the LVEF increased (in group A, from 31% ± 10% to 48% ± 10%, P < 0.01; in group B, from 28% ± 9% to 47% ± 15%, P < 0.01), and the NYHA functional class improved (in group A, from 2.9 ± 0.3 to 1.7 ± 0.5, P < 0.01; in group B, from 2.8 ± 0.6 to 1.7 ± 0.6, P < 0.01). The change in LVEF was mildly correlated with the change in the TDS in group A (r = 0.41) as well as in group B (r = 0.53). In the patients with a favorable response in the TDS or H/M, the NYHA class improved more than in the patients without a favorable response (P < 0.05). Conclusion: Carvedilol treatment can improve cardiac function, symptoms, and cardiac sympathetic nerve activity in patients with DCM to a similar extent as metoprolol treatment. The improvement of cardiac function and symptoms is related to the improvement of cardiac sympathetic nerve activity.

Key Words: 123I-MIBG imaging • metoprolol • carvedilol • dilated cardiomyopathy




This article has been cited by other articles:


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, M. Nakazawa, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, et al.
Prognostic Value of Serial Cardiac 123I-MIBG Imaging in Patients with Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
J. Nucl. Med., June 1, 2008; 49(6): 907 - 914.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure
J. Nucl. Med., December 1, 2007; 48(12): 1993 - 2000.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
P. A. Gould, G. Kong, V. Kalff, S. J. Duffy, A. J. Taylor, M. J. Kelly, and D. M. Kaye
Improvement in cardiac adrenergic function post biventricular pacing for heart failure
Europace, September 1, 2007; 9(9): 751 - 756.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure
Heart, October 1, 2006; 92(10): 1434 - 1440.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. Cohen-Solal, F. Rouzet, A. Berdeaux, D. Le Guludec, E. Abergel, A. Syrota, and P. Merlet
Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure
J. Nucl. Med., November 1, 2005; 46(11): 1796 - 1803.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 661 - 667.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.